Saturday, August 17, 2019
    Latest

    AML

    Home AML
    FDA Clears Mustang Bio’s IND for MB-102 (CD123-CAR T)
    AML

    FDA Clears Mustang Bio’s IND for MB-102 (CD123-CAR T)

    0
    Mustang Bio’s MB-102 Granted Orphan Drug Designation for AML
    AML

    Mustang Bio’s MB-102 Granted Orphan Drug Designation for AML

    0
    Novel Combo Drug Effective Against AML
    AML

    VCU Massey Cancer Center Identifies Novel Combo Drug Effective Against AML...

    0
    AML

    (HM)-SCREEN-Japan 01 Program Bringing Precision Medicine Research to AML Patients in...

    0
    Acute Myeloid Leukemia
    AML

    Nanfang Hospital Southern Medical Univ. Study Shows Sorafenib Associated Helps Patients...

    0
    blood
    AML

    Columbia Investigator Discusses Targeted Alpha-particle Therapy for Hematologic Malignancies

    0
    Acute Myeloid Leukemia
    AML

    Innovative Clinical Trial Taking on Acute Myeloid Leukemia

    0
    Lrukemia
    AML

    VOR Biopharma Raises $42 Million to to Fight Hematological Malignancies such...

    0
    AML

    Genetic Screening Rapidly Links Elderly AML Patients to Targeted Therapy

    0
    Leukemia
    AML

    Pfizer Study Evaluates Addition of Glasdegib in AML & High-Risk MDS...

    0
    - Advertisement -

    EDITOR PICKS

    TrialSite News is the only digital media dedicated 100% to transparent and open coverage of clinical research trial sites around the globe. Based in the Silicon Slopes in downtown Salt Lake City, Utah, we are founded by a team of experts in the clinical trials industry and dedicated to transparency, quality and clinical trial innovation.

    159 West Broadway Suite 200
    Salt Lake City, UT 84101

    Contact us: admin@trialsitenews.com
    © TrialSite News, Inc. All Rights Reserved